Your browser doesn't support javascript.
loading
Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System.
Hiroshima, Yuichi; Tamaki, Yoshio; Sawada, Takuya; Ishida, Toshiki; Yasue, Kenji; Shinoda, Kazuya; Saito, Takashi; Kaburagi, Takayuki; Kiyoshima, Moriyuki; Okumura, Toshiyuki; Sakurai, Hideyuki.
Afiliación
  • Hiroshima Y; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan; hiroshima@pmrc.tsukuba.ac.jp.
  • Tamaki Y; Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Sawada T; QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.
  • Ishida T; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
  • Yasue K; Ibaraki Clinical Education and Training Center, University of Tsukuba Hospital, Ibaraki, Japan.
  • Shinoda K; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
  • Saito T; Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Kaburagi T; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
  • Kiyoshima M; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
  • Okumura T; Graduate School of Health Sciences, Ibaraki Prefectural University of Health Sciences, Ibaraki, Japan.
  • Sakurai H; Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.
Anticancer Res ; 42(6): 2989-2995, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35641279
BACKGROUND/AIM: Suppression of respiratory movement is crucial for safe and effective stereotactic body radiotherapy (SBRT). SyncTraX FX4 is a novel device for synchronous respiratory irradiation. The purpose of this study was to evaluate the efficacy and toxicity of SBRT using SyncTraX FX4 for patients with lung cancer. PATIENTS AND METHODS: Patients treated with SBRT using SyncTraX FX4 between November 2017 and August 2020 were included. In all cases, fiducial markers were inserted into the lung, and the total dose administered was 55 or 60 Gy, depending on the distance from the central region of the lung. Acute and late toxicities were reported, and local control, progression-free survival, cancer-specific survival, and overall survival were analyzed. RESULTS: We evaluated 16 patients and 17 sites. The median follow-up period was 14.4 months. In both the acute and late phases, one patient experienced grade 3 radiation pneumonitis; however, grade 4 or higher toxicities were not observed. There was no local recurrence during the observation period, and the overall survival, cancer-specific survival, and progression-free survival at 2 years were 54.6%, 85.1%, and 33.7%, respectively. CONCLUSION: SBRT with SyncTraX FX4 can provide safe and effective treatment for lung cancer patients in poor condition.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Anticancer Res Año: 2022 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Anticancer Res Año: 2022 Tipo del documento: Article Pais de publicación: Grecia